Renal and systemic hemodynamic effects of empagliflozin: Three randomized, double blind, placebo controlled cross-over trials

4 Authors:

5	Steffen Flindt Nielsen, MD ^{1,2} Camilla Lundgreen Duus, MD ^{1,2} Niels Henrik Buus, MD, Ph.D. ^{2,3}
6	Jesper Nørgaard Bech, MD, Ph.D. ^{1,2} and Frank Holden Mose, MD, Ph.D. ^{1,2}
7	
8	
9	Affiliations:
10	¹ University Clinic in Nephrology and Hypertension, Gødstrup Hospital, Denmark
11	² Department of Clinical Medicine, Aarhus University, Denmark
12	³ Department of Renal Medicine, Aarhus University Hospital, Denmark
13	
14	Short title:
15	Renal and systemic hemodynamic effects of empagliflozin
16	
17	Corresponding author:
18	Steffen Flindt Nielsen
19	e-mail: <u>stfnel@rm.dk</u>
20	Adress: Gødstrup Hospital, Hospitalsparken 15, 7400 Herning, Denmark
21	
22	Total word count: 4153 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 Abstract

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve renal outcomes in type 24 25 2 diabetes mellitus (DM2) and chronic kidney disease (CKD). A decrease in renal blood flow 26 (RBF) with attenuation of glomerular hyperfiltration may contribute to this. We examined renal and 27 systemic hemodynamic effects of SGLT2i in relevant patient categories. 28 Methods: Using a double-blind placebo controlled cross-over design we randomized patients with DM2 and estimated glomerular filtration rate (eGFR) >60 ml/min/1.73m² (n=16), patients with 29 DM2 and eGFR 20-60 ml/min/1.73m² (n=17) and patients with non-diabetic CKD and eGFR 20-60 30 ml/min/1.73m² (n=16) to empagliflozin 10 mg daily or placebo for four weeks and crossed over to 31 the opposite treatment after two-week washout. RBF was measured with ⁸²Rubidium positron 32 emission tomography/computed tomography (⁸²Rb-PET/CT), GFR as plasma clearance of 33 ^{99m}Technetium- diethylene-triamine-pentaacetate, while 24-hour blood pressure (BP) and total 34 peripheral vascular resistance (TVR) were recorded using the commercially available Mobil-O-35 graph. 36 Results: Compared to placebo empagliflozin reduced RBF by 6% in the DM2-CKD group 37 38 (p<0.001), while there were non-significant decreases of 4% in the DM2 group and 1% in the CKD

39 group (p=0.29 and 0.72). Empagliflozin reduced GFR, BP and TVR in all groups. Although total

40 renal vascular resistance (RVR) remained unchanged, calculations based on Gomez' equations

41 revealed a reduction of post-glomerular resistance in the DM2 and CKD groups.

42 Conclusion: Short-term empagliflozin treatment reduced RBF in patients with DM2 and CKD,

43 whereas GFR, BP and TVR were reduced in all groups. The lack of reduction in total RVR together

44 with a decrease in post-glomerular resistance and systemic BP suggest SGLT2i protect the

45 glomerulus due to relative pre-glomerular vasoconstriction and post-glomerular vasodilation.

46

47 Registration: EU Clinical Trials Register 2019-004303-12, 2019-004447-80 and 2019-004467-50 48 **Clinical Perspective** 49 50 What is new? This is the first study of the hemodynamic effects of sodium-glucose cotransporter 2 51 • 52 inhibitors in diabetic and non-diabetic chronic kidney disease. We found that the sodium-glucose cotransporter 2 inhibitor empagliflozin reduced renal 53 • 54 blood flow in patients with type 2 diabetes and chronic kidney disease. Empagliflozin reduced blood pressure and total vascular resistance in patients with type 2 55 • 56 diabetes both with and without chronic kidney disease and in patients with non-diabetic 57 chronic kidney disease. 58 What are the clinical implications? 59 This is the first time sodium-glucose cotransporter 2 inhibitors have been shown to decrease 60 renal blood flow in patients with type 2 diabetes, corroborating the hypothesis that they 61 exert clinical benefits through attenuation of hyperfiltration 62 Our findings suggest a combined pre- and post-glomerular hemodynamic response that may 63 • 64 underlie the beneficial clinical effects. The reduction in blood pressure and total peripheral resistance point to a novel vascular 65 • 66 effect of empagliflozin that is present in both patients with and without type 2 diabetes or chronic kidney disease. 67 68 69 70

72 Non-standard abbreviations and acronyms

- 73
- 74 ⁸²Rb-PET/CT: ⁸²Rubidium positron emission tomography/computed tomography
- 75 ^{99m}Tc-DTPA: ^{99m}Technetium-diethylene-triamne-pentaacetate
- 76 AA: abdominal aorta
- 77 ADPKD: autosomal dominant polycystic kidney disease
- 78 AE: adverse event
- 79 BMI: body mass index
- 80 BP: blood pressure
- 81 CKD: chronic kidney disease
- 82 DM1: type 1 diabetes mellitus
- 83 DM2: type 2 diabetes mellitus
- 84 eGFR: estimated glomerular filtration rate
- 85 ERFP: effective renal plasma flow
- 86 EVF: erythrocyte volume fraction
- 87 FF: filtration fraction
- 88 GCP: good clinical practice
- 89 GFR: glomerular filtration rate
- 90 HbA1c: glycated hemoglobin
- 91 IQR: inter quartile range
- 92 MAP: mean arteriel pressure
- 93 P_{GLO}: intra glomerular pressure
- 94 R_a: afferent glomerular arteriolar resistance
- 95 RBF: renal blood flow
- 96 R_e: efferent glomerular arteriolar resistance
- 97 RVR: renal vascular resistance
- 98 SAE: serious adverse event
- 99 SD: standard deviation
- 100 SGLT2i: sodium-glucose cotransporter 2 inhibitors
- 101 TGF: tubulo-glomerular feedback
- 102 TVR: total peripheral vascular resistance
- 103 uACR: urinary albumin/creatinine ratio
- 104 VOI: volume of interest

105 Introduction

Since the emergence of sodium-glucose cotransporter 2 inhibitors (SGLT2i) their precise 106 107 mechanisms of action have been a topic of debate. According to the tubular hypothesis of hyperfiltration, SGLT2i can confer renal protection via changes in renal hemodynamic function [1]. 108 109 SGLT2 is thought to play a key role in the pathophysiology of diabetic nephropathy, mediating 110 reuptake of excessively filtered sodium and glucose thereby decreasing sodium delivery to the macula densa. This triggers a tubulo-glomerular feedback (TGF) response which dilates the afferent 111 112 arteriole increasing renal blood flow (RBF) and glomerular pressure, leading to hyperfiltration and 113 elevated glomerular filtration rate (GFR). Long term hyperfiltration can lead to glomerular injury and chronic kidney disease (CKD) [2]. Conversely, blockage of SGLT2 reduce sodium and glucose 114 115 reuptake which increases distal sodium delivery, causing afferent arteriolar vasoconstriction, decreased RBF and alleviation of hyperfiltration, resulting in kidney protection [3-6]. Cherney et al. 116 showed that treatment with empagliflozin reduced effective renal plasma flow (ERPF) and GFR in 117 younger patients with type 1 diabetes (DM1), indicating ameliorated glomerular hyperfiltration [7] 118 119 and studies in mice have demonstrated that empagliflozin can induce afferent arteriolar 120 vasoconstriction and reduce hyperfiltration at the single nephron level [8].

121

In patients with DM2 and/or CKD initiation of SGLT2i is associated with an acute, but reversible, reduction in estimated GFR (eGFR) [9] whereafter it stabilizes, mitigating further decline in renal function [10, 11]. This acute eGFR reduction is not related to increased risk of renal events; on the contrary it predicts better outcomes [12, 13]. This seems to corroborate the above hypothesis, however none of the studies examining renal hemodynamic effects of SGLT2i in patients with DM2 have been able to document a decrease in RBF [14-16]. One explanation could be that the

hemodynamic effects of SGLT2i differ between patients with DM1 and DM2 with post-glomerular
vasodilation being more prominent in the latter [17].

130

Despite the extensive use of SGLT2i in patients with diabetic and non-diabetic CKD, their 131 hemodynamic effects have not been studied in these groups. Therefore, we examined the renal and 132 133 systemic hemodynamic effects of empagliflozin in patients with DM2 with and without concomitant CKD as well as in patients with non-diabetic CKD, reflecting the patient categories 134 who are offered SGLT2i treatment. We employed a novel ⁸²Rubidium positron emission 135 tomography/computed tomography (82Rb-PET/CT) method for estimating RBF, our primary 136 endpoint. Secondary endpoints included GFR, 24-hour ambulatory blood pressure (BP), total 137 138 peripheral vascular resistance (TVR) and renal vascular resistance (RVR). We hypothesized that 139 empagliflozin would reduce RBF and decrease GFR and BP in all groups.

140

141 Methods

142 Design

143 We conducted three randomized, double-blind, placebo controlled, single centre cross-over studies including participants with DM2 and preserved kidney function (DM2 group), DM2 and 144 concomitant CKD (DM2-CKD group) and non-diabetic CKD (CKD group). The design and 145 146 methods of our project, the so called SiRENA project, have been previously published [18]. Here, we report the primary endpoint and selected secondary outcomes. The experimental setup was 147 148 identical in the three studies (Figure 1). Briefly, participants were randomized to four weeks of 149 treatment with either empagliflozin 10 mg daily or matching placebo and crossed over to four 150 weeks of the opposite treatment after a wash out period of at least 2 weeks. Study endpoints were measured at an examination day at the end of each treatment period. If participants were on an 151

SGLT2i at inclusion, it was discontinued at least two weeks prior to randomization. If necessary, it could be substituted to a different class of anti-diabetic treatment in accordance with national treatment guidelines. All other medications were kept unaltered. Four days prior to each examination, participants were encouraged to adhere to their usual diet and fluid intake was standardized.

157

158 *Study participants*

159 All participants were informed of the study purpose and methods and signed consent was obtained before screening. Participants were screened prior to inclusion, ensuring they fulfilled all inclusion 160 161 and no exclusion criteria. Inclusion criteria were: Age > 18 years, DM2 with a glycated hemoglobin 162 (Hb1Ac) between 48-70 mmol/mol, diagnosed at least one year prior to inclusion and on stable antidiabetic treatment for at least 3 months (DM2 and DM2-CKD groups) and eGFR > 60 163 ml/min/1.73m² (DM2-group) or 20-60 ml/min/1.73m² (DM2-CKD and CKD-groups). Fertile 164 women were to use safe contraception. Exclusion criteria were: Anamnestic or clinical signs of 165 166 heart- or liver failure, active malignancies besides non-melanoma skin-cancers, body mass index $(BMI) > 35 \text{ kg/m}^2$, pregnancy or nursing, alcohol or substance abuse, allergies or unacceptable side 167 effects to the study medication, previous kidney transplantation, autosomal dominant polycystic 168 169 kidney disease (ADPKD), DM1 (or DM2 for the CKD group) or if participants were deemed unfit 170 to complete the trial. The studies were approved by The Central Denmark Region Committees on Health Research Ethics and the Danish Medicines Agency and were conducted in accordance with 171 172 the Declaration of Helsinki 2013. The studies were monitored by the Good Clinical Practice (GCP) 173 Unit of Aarhus and Aalborg Universities.

175 *Statistics and sample size calculation*

Normality was evaluated using histograms and QQ-plots. Variance was evaluated using Bland-176 177 Altman and scatter plots. If non-normally distributed, normality was tested on the logarithmic scale. Paired t-test was applied to normally distributed data and is presented as mean \pm standard deviation 178 179 (SD) or as geometric mean [inter quartile range (IQR)] if on the log scale. The sign-test was applied 180 to non-parametric data. Potential period and carry-over effects were assessed using a linear mixed effects model with treatment, period and carry-over as fixed effects and participant ID as a random 181 182 effect. Between-group differences were tested using a linear mixed effects model, allowing for unequal variance. p-values <0.05 were considered statistically significant. A power calculation was 183 performed on the primary endpoint. Fifteen patients were needed in each study to detect a minimal 184 185 relevant difference in RBF of 0.167 ml/min/ccm, with a SD of 0.180 ml/min/ccm, a two-sided α level of 5% and a power of 90%. All statistical analyses were done using STATA version 18.0 186 (StataCorp LLC, College Station, Texas, US). 187

188

189 Study methods:

190 *RBF*

RBF was estimated based on renal uptake of ⁸²Rb measured with ⁸²Rb-PET/CT scans. Scanning 191 procedure and data analysis was performed as described by Langaa et al. [19, 20]. In short, a low 192 dose CT scan was used for attenuation correction. Following bolus injection of 555 MBq of ⁸²Rb, 193 an 8-minute dynamic PET-scan was performed with the abdominal aorta (AA) and both kidneys 194 within the same field of view. Renal ⁸²Rb activity was estimated using image based iso-contouring 195 196 of both kidneys. AA activity was defined by placing a volume of interest (VOI) within the proximal AA. Time activity curves were generated on the basis hereof (see Figure S1). We estimated RBF 197 (ml/min/ccm) for each kidney as the single kidney K₁-value using a 1-tissue compartment model 198

based on renal ⁸²Rb activity uptake with AA activity as input function. Mean RBF was estimated for each participant as the mean K_1 -value. AA measurements were corrected for partial volume and spill-over and all measurements were β -corrected as has been previously described. Analyses were made using PMOD[®] (PMOD Technologies Ltd., Zürich, Switzerland). Total RBF (ml/min) was assessed by multiplying RBF with kidney volume as estimated by the renal iso-contours using the formula:

205
$$Total RBF = RBF_{right \, kidney} * V_{right \, kidney} + RBF_{left \, kidney} * V_{left \, kidney}.$$

206 Effective renal plasma flow (ERPF) was calculated as

ERPF = RBF * (1 - Erythrocyte Volume Fraction (EVF))

207

208 *GFR*

GFR was measured by clearance of ^{99m}Technetium- diethylene-triamine-pentaacetate (^{99m}Tc-DTPA). First, a zero sample was drawn. Hereafter 25 MBq of ^{99m}Tc-DTPA was injected intravenously and blood samples were drawn after three, four and five hours, measuring residual plasma activity. Measurements were standardized for height and weight.

213

214 Systemic hemodynamics

24-hour BP, heart rate and TVR were measured using a Mobil-O-Graph® (I.E.M. GmbH., Aachen,
Germany). The Mobil-O-Graph was placed on the upper forearm at the beginning of the
examination day and was removed 24 hours later. Measurements were done every 20th minute.

218

219 Renal hemodynamic calculations

Filtration fraction (FF) was calculated as $FF = \frac{GFR}{total ERPF}$. Mean arterial pressure (MAP) was calculated as MAP = diastolic BP + $\frac{(systolic BP-diastolc BP)}{3}$, where day-time BP values were used.

222 Renal vascular resistance (RVR) was calculated as $RVR = \frac{MAP}{total RBF}$. Intra glomerular pressure 223 (P_{GLO}), afferent and efferent glomerular arteriolar resistance (R_a and R_e) were estimated using the 224 Gomez equations [21].

- 225
- 226 Biochemical analysis

Plasma and urine samples were analysed by the Department of Clinical Biochemistry, Gødstrup Hospital as routine procedures, except for urinary glucose which was measured using an Invitrogen Glucose Colorimetric Detection Kit (ThermoFisher Scientific Inc., Waltham, MA. USA). eGFR was calculated using the CKD-EPI formula. Urinary albumin/creatinine ratio (uACR) was calculated based on measurements of urinary albumin and creatinine from the total voided volume during the examination day (collection time: 5 hours)

- 233
- 234 Results

Inclusion began in April 2021 and was completed by September 2022. Examinations were completed by December 2022. 49 participants completed the studies; 16 in the DM2 group, 17 in the DM2-CKD group and 16 in the CKD group. For further elaboration on inclusion and exclusion, see Figure 2. Baseline characteristics are described in Table 1.

- 239 240
- 241 Renal Blood Flow
- 242 Due to poor image quality, two participants were excluded from the analysis, one in the DM2 group
- and one in the DM2-CKD group. In the DM2-CKD group empagliflozin reduced RBF by 6%
- 244 (geometric mean ratio: 0.94, 95% CI: 0.91; 0.97, p < 0.001). There were non-significant reductions
- of 4% in the DM2-group and 1% in the CKD-group (p = 0.29 and 0.72). Changes in RBF were not

246	significantly different between groups ($p = 0.16$). There was no specific period ($p = 0.53$) or carry-
247	over effect ($p = 0.82$). The RBF results are presented in Table 2 and Figure 3.
248	
249	GFR
250	Empagliflozin significantly reduced GFR in all groups as compared to placebo. GFR was reduced
251	by 14% in the DM2 group (p < 0.001), by 9 % in the DM2-CKD group (p = 0.019) and by 11% in
252	the CKD group ($p = 0.018$). Changes between groups did not significantly differ ($p = 0.36$). There
253	was no period or carry over effect ($p = 0.98$). GFR results are presented in Table 2 and Figure 4.
254	
255	Systemic hemodynamics
256	Empagliflozin treatment reduced 24-hour systolic blood pressure by 5 mmHg in the DM2 group
257	(95%CI: -9; -1 mmHg, $p = 0.015$), as compared to placebo. The mean reduction was 7 mmHg
258	(95%CI: -12; -2 mmHg, p = 0.0097) in the DM2-CKD group and 4 mmHg in the CKD-group
259	(95% CI: -9; 0 mmHg, $p = 0.066$). Empagliflozin lowered TVR in all groups. There was no period
260	or carry over effects ($p = 0.70$ and 0.79). Heart rate did not change. One patient from the DM2
261	groups was excluded from this analysis due to missing data. See Table 3 and Figure 5.
262	
263	Renal hemodynamics
264	RVR did not change during empagliflozin treatment in any of the groups. FF was reduced by 9% in
265	the DM2 group ($p = 0.028$), with no detectable change in the DM2-CKD or CKD groups ($p = 0.42$
266	and 0.72, respectively). P_{GLO} significantly decreased in the DM2 group with no change in the two
267	other groups. R_e decreased in the DM2 and CKD groups. R_a did not change in any of the groups.
268	Results are presented in Table 2.
269	

270 *Changes in glucose and albuminuria*

Analysis of uACR only included participants with an uACR of at least 30 mg/g at the placebo visit. Empagliflozin significantly reduced uACR by 49% in the DM2-CKD group (p = 0.014). Although uACR was reduced by 50% in the DM2 group and 20% in the CKD group, these changes did not reach statistical significance (p =0.07 and p = 0.24, respectively). HbA1c did not change between treatments. Urinary glucose excretion was increased in all groups during empagliflozin treatment compared to placebo. See Table S2.

277

278 *Adverse events*

279 The 58 participants who underwent randomization were evaluated for adverse events (AEs). AEs 280 were classified as either related to empagliflozin or placebo treatment. If an AE happened during 281 wash-out, it was ascribed to the previous treatment. 14 participants experienced an AE while treated with empagliflozin, while 19 participants experienced an AE on placebo. Details are presented in 282 Table S1. Two participants dropped out due to AEs, one due to vaginal candidiasis during 283 284 empagliflozin treatment and one due to an episode of dehydration and worsening of renal function 285 during placebo treatment. One participant experienced a serious adverse event (SAE) of severe 286 erysipelas requiring hospitalization and intra-venous antibiotics. This happened during wash-out 287 after placebo treatment. One participant underwent an elective amputation of a toe due to a pre-288 existing chronic ulcer present before study enrolment. The amputation occurred during placebo 289 treatment.

290

291 Discussion

Our main finding is that empagliflozin reduced RBF in patients with DM2 and concomitant CKD.There was a smaller, non-significant decrease in the DM2 group and no change in the CKD group.

294	This is the first time SGLT2i have been shown to affect RBF in patients with DM2. Furthermore,
295	empagliflozin decreased GFR in all groups, reflecting the known acute reduction. [11, 22]. Our
296	findings support the hypothesis that SGLT2i alleviate hyperfiltration in diabetic nephropathy.
297	While, per definition, no participants in the DM2-CKD group had hyperfiltration defined as
298	elevated GFR, it could still be present at the single nephron level [23] and the decrease in RBF and
299	GFR we observe could indicate that empagliflozin reverses the TGF mediated feedback response,
300	normalizes afferent arteriolar tone and diminishes hyperfiltration.
301	
302	Another important finding is that empagliflozin decreased TVR in all groups, regardless of DM2 or

303 CKD status. That SGLT2i decreases TVR has been reported in DM1, but to our knowledge never in 304 DM2 or CKD [24]. These findings suggest a novel anti-hypertensive mechanism, perhaps related to 305 a direct vasodilatory effect [25, 26]. Furthermore, we observed a clinically meaningful decrease in 306 ambulatory BP in all groups during empagliflozin treatment in line with the existing evidence [27]. 307 The lack of statistical significance in the CKD group probably reflects a small sample size rather 308 than an absence of effect in this population.

309

RBF decreased significantly in the DM2-CKD group only. Between-group differences should be 310 311 interpreted cautiously as the project was not designed for such comparisons, and while there was no 312 statistical difference in RBF changes between groups, the change seems most pronounced in the 313 DM2-CKD group. Diabetic kidney disease is characterized by overexpression and over activation 314 of SGLT2 [28, 29] and sodium reabsorption - the main driver of TGF - increases during episodes 315 of hyperglycaemia [30, 31]. Our findings suggest that individuals with diabetes and CKD 316 experience a more prominent TGF response to SGLT2i. It is noteworthy that while the relative effects of SLGT2i on renal outcomes are similar across different patient categories [32], there is 317

318 greater absolute treatment benefit in DM2 patients with both albuminuria and reduced eGFR [33]. 319 Interestingly, it is also in patients with both DM2 and CKD we observe a marked decrease in RBF. 320 However, as we examined only short-term effects, we cannot say if the changes we describe persist 321 during chronic treatment or how they relate to the long-term benefits. 322 In the CKD group RBF did not change. The hemodynamic effects of SGLT2i have not previously 323 been examined in patients with non-diabetic CKD and though our limited sample size prevents us from reaching a clear conclusion, our results could indicate that SGLT2 mediated changes in RBF 324 325 could be less pronounced non-diabetic CKD than in diabetic nephropathy. Similarly, SGLT2i 326 induce TGF responses less consistently in animal models with non-diabetic CKD than in those with 327 diabetic nephropathy [34]. 328 329 GFR decreased in all groups, while RBF decreased significantly in the DM2-CKD group only, suggesting GFR changes are not solely dependent on RBF. While identifying the exact mechanisms 330 331 by which SGLT2i impact GFR is beyond the scope of this paper, several potential explanations 332 could be considered. One possibility relates to the interplay between afferent- and efferent arteriolar 333 resistance. While GFR and RBF respond in parallel to changes in afferent arteriolar resistance, 334 changes in efferent resistance can dissociate autoregulation of GFR from RBF [35]. It has previously been suggested that SGLT2i can alleviate hyperfiltration through dilation of the efferent 335 336 arteriole, eliciting a decrease in GFR without affecting RBF [36]. However, GFR is not determined 337 solely by glomerular pressure; intra-tubular pressure and properties of the glomerular filtration 338 barrier could also be of importance. By inhibiting solute reabsorption from the distal tubule,

339 SGLT2i could theoretically increase tubular pressure leading to reduced pressure gradient across the

340 glomeruli and a decrease in GFR [37]. Additionally, animal studies have shown that dapagliflozin

can directly affect podocyte function [38]. SGLT2i could thus potentially exert non-hemodynamiceffects on GFR.

343

We calculated estimates of intra-renal hemodynamics to further explore the hemodynamic effects of 344 SGLT2i. These calculations are indirect and can at best be indicative of the underlying physiology; 345 346 the Gomez equations rely on assumptions of normal renal physiology which do not align with the 347 characteristics of our cohort, particularly those with CKD. Furthermore, potential non-348 hemodynamic effects on GFR are not taken into account [21]. Nevertheless, as more direct methods 349 in humans are lacking, they provide our best estimates. Using these estimates, we found that 350 empagliflozin decreased FF, P_{GLO} and R_e in the DM2 group, which is in agreement with previous 351 findings from van Bommel et al. who studied a comparable cohort of patients with DM2 and preserved kidney function [15]. This supports the current view that SGLT2i could exert effect in 352 353 DM2 partly through dilation of the efferent glomerular arteriole. We saw a decrease in R_e in the 354 CKD group as well, perhaps indicative of a similar mechanism. 355 356 Despite significant changes in RBF in the DM2-CKD group, we observed no change in RVR in this 357 or any other group, nor did R_a change. This seemingly contrasts the results from Cherney et al., who found that empagliflozin decreased ERPF and increased RVR in patients with DM1 and 358 359 hyperfiltration, indicating an increase in pre-glomerular resistance [7]. We do not, however, believe our findings preclude an SGLT2i induced effect the afferent arteriole. While R_a did not change, 360 361 TVR decreased significantly. This is noteworthy, since we would have expected a parallel auto

- regulatory decrease in R_a to conserve RBF as has previously been described with for example
- angiotensin receptor blockers [39]. That R_a did not decrease while RBF did suggests a SLGT2i-

induced relative afferent vasoconstriction. Our findings thus indicate a combined afferent and
efferent arteriolar response. Similar mechanisms were described in a study in diabetic rats [40].

We measured RBF using a novel ⁸²Rb-PET/CT method. The method has low intra-assay variability 367 and excellent inter-observer reliability, allowing for precise and reliable measurements of relative 368 369 changes in perfusion [20]. When studying SGLT2i, it has the further advantage compared to para-370 amino-hippuric acid (PAH) of not being affected by glycosuria [41]. There are disadvantages to the method as well; ⁸²Rb-PET/CT likely underestimates perfusion at high perfusion rates [15] and the 371 method cannot distinguish between cortical and medullar perfusion [19, 42]. Furthermore, ⁸²Rb is a 372 373 potassium analogue and thus not an inert tracer and we have not taken potential urinary excretion into account [42]. Altogether, ⁸²Rb-PET/CT likely underestimates true RBF, which can explain why 374 375 the measured values are lower than what have previously been described [15], in a cross over design, absolute values are of less importance as we examine changes within the same individual. 376 Our project has other limitation; the small sample sizes make comparisons between groups difficult. 377 378 Furthermore, changes in RBF were smaller and variability larger than anticipated in the power 379 calculation, so we cannot rule out potential effects in the DM2 and CKD-groups had the sample 380 sizes been larger. Inclusion in the DM2-CKD group did not require a biopsy verified diagnosis of 381 diabetic nephropathy, so other aetiologies of CKD could be present. Likewise, in the CKD-group 382 the cause of CKD was not reported in half the participants, limiting generalizability. We did not employ glycaemic clamping method nor were participants fasting. While this may add uncertainty 383 384 to the results, an advantage is that our approach more accurately reflects both the patient 385 populations and conditions in which SGLT2i would be used in a real-world setting. 386 In conclusion, short-term empagliflozin treatment significantly reduces RBF in patients with DM2 and concomitant CKD as compared to placebo, while GFR, BP and TVR was reduced in all groups. 387

Our findings suggest that the renal hemodynamic effects of SGLT2i could be caused by relative
 pre-glomerular vasoconstriction, as well as post-glomerular vasodilation.

390

391 Funding

This project was funded by The Augustinus Foundation, The Research Foundation of the Central Denmark Region, The Medicine Fund of the Danish Regions, Gødstrup Hospital Research Fund and Boehringer-Ingelheim, who delivered the study medication. Boehringer-Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as it relates to a Boehringer-Ingelheim substance, as well as intellectual property considerations. Boehringer-Ingelheim had no role in the design, analysis, interpretation of the results or the writing of this manuscript.

399

400 Authors contribution

401 All authors contributed to the manuscript. SFN, FHM, NHB and JNB designed the trials, which

402 were conducted by SFN with support from CLD and FHM. SFN analyzed the data and

403 interpretation was done in cooperation with FHM, JNB and NHB. SFN drafted the manuscript

404 which was revised and accepted by all authors.

405

406 Acknowledgements

We would like to thank the biomedical laboratory scientists at The University Clinic in Nephrology
and Hypertension and The Department of Nuclear Medicine, Gødstrup for making this project
possible. Special thanks to Lene Ring Madsen and STENO Diabetes Center, Aarhus for helping
with recruitment in the DM2-CKD group and to Stine Sundgaard Langaa for kindly helping with
the analysis of the Rb⁸²-PET/CT scans.

412

413	Conflict o	of interest	disclosures
-----	------------	-------------	-------------

414	SFN has disclosed	travel expenses	covered by AstraZ	Zeneca. FHM disclosed	advisory board
-----	-------------------	-----------------	-------------------	-----------------------	----------------

- participation and speaker honoraria from Boehringer-Ingelheim and AstraZeneca. JBN disclosed
- advisory board participation for Bayer, Boehringer-Ingelheim and AstraZeneca. No other
- disclosures were reported.

Data sharing

420	All study	data	will be	made	available	upon	request.
-----	-----------	------	---------	------	-----------	------	----------

438	1.	Vallon, V. and S.C. Thomson, The tubular hypothesis of nephron filtration and diabetic
439		<i>kidney disease.</i> Nat Rev Nephrol, 2020. 16 (6): p. 317-336.
440	2.	Wright, E.M., SGLT2 Inhibitors: Physiology and Pharmacology. Kidney360, 2021. 2(12):
441		p. 2027-2037.
442	3.	Vallon, V. and S. Verma, Effects of SGLT2 Inhibitors on Kidney and Cardiovascular
443		<i>Function,</i> Annu Rev Physiol, 2021, 83 : p. 503-528.
444	4.	Vallon, V., Renoprotective Effects of SGLT2 Inhibitors, Heart Fail Clin, 2022, 18 (4); p.
445		539-549
446	5	Packer M Lack of durable natriuresis and objective decondestion following SGLT2
447	5.	inhibition in randomized controlled trials of natients with heart failure. Cardiovasc
118		Diabetol 2023 22 (1): p 107
440	6	Scholtos DA ot al Natriuratic Effect of Two Weeks of Dapadiflazin Treatment in
449	0.	Patients With Type 2 Diabates and Preserved Kidney Eurotion During Standardized
450		Sedium Inteles, Desulta of the DADACALT Trial Disbetes Care 2021 44 (2), p. 440
451		Soulum Intake: Results of the DAPASALT Indi. Diabetes Care, 2021. 44(2): p. 440-
452	-	
453	7.	Cherney, D.Z., et al., Renal hemodynamic effect of sodium-glucose cotransporter 2
454		inhibition in patients with type 1 diabetes mellitus. Circulation, 2014. 129 (5): p. 587-
455		97.
456	8.	Kidokoro, K., et al., Evaluation of Glomerular Hemodynamic Function by Empagliflozin
457		in Diabetic Mice Using In Vivo Imaging. Circulation, 2019. 140 (4): p. 303-315.
458	9.	Perkovic, V., et al., Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med
459		Res Opin, 2015. 31 (12): p. 2219-31.
460	10.	Herrington, W.G., et al., Empagliflozin in Patients with Chronic Kidney Disease. N Engl J
461		Med, 2023. 388 (2): p. 117-127.
462	11.	Kraus, B.J., et al., Characterization and implications of the initial estimated glomerular
463		filtration rate ‘:dip’: upon sodium-alucose cotransporter-2 inhibition
464		with empagliflozin in the EMPA-REG OUTCOME trial. Kidney International, 2021, 99 (3):
465		n 750-762
466	12	Adamson C et al Initial Decline (Din) in Estimated Glomerular Filtration Rate After
467	121	Initiation of Danadliflozin in Patients With Heart Failure and Reduced Fiection Fraction
468 468		Insights From DAPA-HE Circulation 2022 146 (6): p. 438-449
460	12	Hourspink Hill and D.7 I. Charnov, Clinical Implications of an Acute Din in aCEP after
409	15.	SCI T2 Inhibitor Initiation Clin 1 Am Soc Nonbrol 2021 16 (9): n 1279 1290
470	11	Ott C ot al Denal homodynamic offects differ hotwarn antidiabatic combination
4/1	14.	Ott, C., et al., Renal hemodynamic effects unter between antidiabetic combination
4/2		strategies: randomized controlled clinical trial comparing empagiifiozin/linagiiptin with
4/3		metrormin/insulin giargine. Cardiovasc Diabetol, 2021. 20 (1): p. 178.
4/4	15.	van Bommei, E.J.M., et al., The renal hemodynamic effects of the SGL12 inhibitor
4/5		dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular
476		vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized,
477		<i>double-blind RED trial.</i> Kidney Int, 2020. 97 (1): p. 202-212.
478	16.	Scholtes, R.A., et al., Kidney Hemodynamic Effects of Angiotensin Receptor Blockade,
479		Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover
480		Randomized Trial in People With Type 2 Diabetes. Circulation, 2022. 146(24): p. 1895-
481		1897.
482	17.	van Bommel, E.J.M., et al., Renal hemodynamic effects of sodium-glucose cotransporter
483		2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2
484		diabetes and normal kidney function. Kidney Int, 2020, 97 (4); p. 631-635.
485	18.	Nielsen SF, D.C., Buus NH, Bech JN, Mose FH, Empagliflozin in type 2 diabetes with and
486		without CKD and non-diabetic CKD: Protocol for 3 randomized, double-blind, placebo
487		controlled cross-over trials -The SiRFNA project. 1MIR Research Protocols
488		25/04/2024:56067 (forthcoming/in press), 2024
489	19	Langaa S S et al Estimation of renal perfusion based on measurement of rubidium-
409	ту.	82 clearance by PET/CT scanning in healthy subjects EINIMMI Drug 2021 Q(1) n A2
750		oz cicarance by relyct scanning in nearing subjects, conversion, rugs, 2021. $o(1)$: p . 45.

- 491 20. Langaa, S.S., et al., *Reliability of rubidium-82 PET/CT for renal perfusion determination*492 *in healthy subjects.* BMC Nephrol, 2022. 23(1): p. 379.
- 493 21. Bjornstad, P., et al., *The Gomez' equations and renal hemodynamic function in kidney disease research.* Am J Physiol Renal Physiol, 2016. **311**(5): p. F967-f975.
- 495 22. Meraz-Muñoz, A.Y., J. Weinstein, and R. Wald, *eGFR Decline after SGLT2 Inhibitor*496 *Initiation: The Tortoise and the Hare Reimagined.* Kidney360, 2021. 2(6): p. 1042497 1047.
- 49823.Fattah, H., A. Layton, and V. Vallon, How Do Kidneys Adapt to a Deficit or Loss in499Nephron Number? Physiology (Bethesda), 2019. **34**(3): p. 189-197.
- Lytvyn, Y., et al., *Renal and Vascular Effects of Combined SGLT2 and Angiotensin- Converting Enzyme Inhibition.* Circulation, 2022. **146**(6): p. 450-462.
- 502 25. De Stefano, A., et al., *Mechanisms of SGLT2 (Sodium-Glucose Transporter Type 2)*503 *Inhibition-Induced Relaxation in Arteries From Human Visceral Adipose Tissue.*504 Hypertension, 2021. **77**(2): p. 729-738.
- 505 26. Li, H., et al., *The anti-diabetic drug dapagliflozin induces vasodilation via activation of* 506 *PKG and Kv channels.* Life Sci, 2018. **197**: p. 46-55.
- 507 27. Heerspink, H.J., et al., *Dapagliflozin and Blood Pressure in Patients with Chronic Kidney*508 *Disease and Albuminuria.* Am Heart J, 2024.
- Vallon, V., *Glucose transporters in the kidney in health and disease.* Pflugers Arch,
 2020. 472(9): p. 1345-1370.
- 511 29. Wang, X.X., et al., SGLT2 Protein Expression Is Increased in Human Diabetic
 512 Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION,
 513 INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE. J Biol
 514 Chem, 2017. 292(13): p. 5335-5348.
- 51530.Rajasekeran, H., D.Z. Cherney, and J.A. Lovshin, Do effects of sodium-glucose516cotransporter-2 inhibitors in patients with diabetes give insight into potential use in517non-diabetic kidney disease? Curr Opin Nephrol Hypertens, 2017. 26(5): p. 358-367.
- 51831.Pollock, C.A., et al., Tubular sodium handling and tubuloglomerular feedback in519compensatory renal hypertrophy. Pflugers Arch, 1992. **420**(2): p. 159-66.
- 32. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on
 kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet,
 2022. 400(10365): p. 1788-1801.
- 33. Neuen, B.L., et al., *Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.* Am J Kidney Dis, 2021. **77**(1): p. 23-34.e1.
- 526 34. Upadhyay, A., *SGLT2-Inhibitors and Kidney Protection: Mechanisms Beyond Tubulo-*527 *Glomerular Feedback.* Kidney360, 2024.
- 528 35. Carlström, M., C.S. Wilcox, and W.J. Arendshorst, *Renal autoregulation in health and disease.* Physiol Rev, 2015. **95**(2): p. 405-511.
- 53036.Kim, N.H. and N.H. Kim, Renoprotective Mechanism of Sodium-Glucose Cotransporter 2531Inhibitors: Focusing on Renal Hemodynamics. Diabetes Metab J, 2022. 46(4): p. 543-532551.
- 53337.Persson, P., P. Hansell, and F. Palm, *Tubular reabsorption and diabetes-induced*534glomerular hyperfiltration. Acta Physiol (Oxf), 2010. **200**(1): p. 3-10.
- 535 38. Cassis, P., et al., SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric
 536 nondiabetic nephropathy. JCI Insight, 2018. 3(15).
- Buus, N.H., et al., *Renal resistance and long-term blood pressure in individuals genetically predisposed for essential hypertension: 10-year follow-up of the Danish Hypertension Prevention Project.* J Hypertens, 2016. **34**(6): p. 1170-7.
- 540 40. Thomson, S.C. and V. Vallon, *Effects of SGLT2 inhibitor and dietary NaCl on glomerular*541 *hemodynamics assessed by micropuncture in diabetic rats.* Am J Physiol Renal Physiol,
 542 2021. **320**(5): p. F761-f771.
- 543 41. Scholtes, R.A., et al., *Glucosuria Interferes With Measurement of Effective Renal Plasma*544 *Flow Using para-Aminohippuric Acid, With a Focus on SGLT2 Inhibitors.* Kidney Int Rep,
 545 2020. 5(11): p. 2052-2054.

- Green, M.A. and G.D. Hutchins, *Positron emission tomography (PET) assessment of renal perfusion.* Semin Nephrol, 2011. **31**(3): p. 291-9.
- 548

549 Figures



550

551 Figure 1: Study design. Schematic view of the study design

552

553



Figure S1. ⁸²**Rb-PET/CT renal scan. A:** Renal activity of ⁸²Rb with iso-contours of the right and left kidney (green and turquoise), coronal view. **B and C:** The abdominal aorta (AA) with volume of interest (VOI) (red) and a background box for partial volume correction (orange), sagittal and coronal views. **D:** Time activity curves of ⁸²Rb activity in the AA (red), right and left kidney (green and turquoise) and AA background (orange)

- 561
- 562
- 563
- 564
- 565
- 566



- **Figure 2:** Flow-chart of screening, inclusion, and exclusion for all studies.





- ____







Figure 5: 24-hour systolic blood pressure (BP), and total vascular resistance (TVR) with mean and
95% confidence interval (95%CI).

604

606 Tables:

	DM2	DM2-CKD	СКD	
Age (years)	68.0 ± 8.5	71.2 ± 5.2	66.9 ± 8.2	
Male sex (%)	69%	94%	56%	
BMI (kg/m²)	28.4 ± 4.1	29.9 ± 3.6	27.2 ± 4.8	
Hba1c (mmol/mol)	55 ± 6.2	56 ± 4.6	37 ± 2.6	
eGFR (ml/min/1.73m ²)	84.9 ± 13.7	39.0 ± 8.6	34.8 ± 10.8	
Duration of diabetes (years)	15.6 ± 8.5	14.8 ± 7.7	-	
Duration of kidney disease (years)	-	9.3 ± 4.9	7.3 ± 5.6	
Reported cause of kidney disease	-			
Diabetic		82%	0%	
Hypertensive		0%	19%	
Nephrosclerosis		0%	19%	
Retroperitoneal fibrosis		6%		
Granulomatosis w. polyangiitis		0%	6%	
Focal segmental glomerular sclerosis		6%	0%	
Unknown		12%	50%	
Hypertension (%)	75%	100%	100%	
Ischemic heart disease (%)	19%	24%	19%	
Number of anti-hypertensive medications (n)	2.5 [1-4]	3 [2-4]	3 [2-4]	
On insulin (%)	31%	59%	-	
On SGLT2i (%)	43%	59%	6%	
On ACEi or ARB (%)	63%	82%	81%	
On diuretics (thiazide or loop diuretics) (%)	44%	59%	50%	
uACR (mg/g)	30 [9 - 275]	107 [40 - 1060]	187 [57 - 1622]	
uACR > 30 mg/g (%)	25%	76%	75%	
Current or former smokers (%)	57%	6%	19%	

607	Table 1: Baseline demographics. Data is presented as mean \pm SD or median [interquartile range].
608	BMI: body mass index, HbA1c: glycated hemoglobin, eGFR: estimated glomerular filtration rate,
609	uACR: urinary albumin/creatinine ratio, SGLT2i: sodium-glucose cotransporter 2 inhibitors, ACEi:
610	angiotensin converting enzyme inhibitors, ARB: angiotensin receptor blockers.
611	
612	
613	
614	
615	
616	
617	
618	
619	
620	
621	
622	
623	
624	
625	
626	
627	
628	
629	
630	
631	
632	
633	

Event	Empagliflozin	Placebo
Number of participants with an adverse event:	14	19
Hypoglycemia	1	2
Musculoskeletal	2	6
Urogenital infections	2	1
Dizziness	2	3
Headache	0	1
Infection	2	2
Fatigue	1	0
Amputation (toe)	0	1
Hyperglycemia	0	1
Polyuria	1	0
Diarrhea	1	1
Dehydration	0	1
Worsening of renal function	0	1
Hyponatremia	0	1
Other	5	4

634 **Table S1:** Adverse events

		DM2 Gr		DM2-CKD group				CKD group				
	Empagliflozin Mean± SD	Placebo Mean± SD	Difference Mean (95% CI)	p-value	Empagliflozin Mean± SD	Placebo Mean± SD	Difference Mean (95% CI)	p-value	Empagliflozin Mean± SD	Placebo Mean± SD	Difference Mean (95% CI)	p-value
24-hour systolic BP	131 + 12	135 + QM2 gro	oup -5	0.015	132 + 12	1 DM2-CKD g	roup - 7	0.0097	122 + 13	126 + ÇKD gr	oup -4	0.066
(mmHg)	Empagliflozin	Placebo	(-9; Difference	n-value	Empagliflozin	Placebo	(-bifference	n-value	Empagliflozin	Placebo	Difference	n-value
24-hour diastolic BP (mmHg)	77 ± 10	79 ± 8	- 2 (-5; 0)	0.029	76 ± 7	80 ± 9	- 3 (-7; 0)	0.043	77 ± 10	79 ± 9	- 2 (-5; 1)	0.10
(ml/min/ccm)	[1.27-1.85]	[1.33-1.90]	(0.90; 1.03)	0.29	[0.82-1.17]	[0.89-1.15]	(0.94)	0.001	[0.96-1.34]	[0.99-1.42]	(0.94; 1.05)	0.72
Total Renal Blood Flow (ml/min)	458 [375–581]	475 [324–598]	0.96 (0.90; 1.03)	0.30	262 [214–333]	280 [235–344]	0.94 (0.91; 0.97)	0.001	227 [136-320]	229 [165-328]	0.99 (0.94; 1.04)	0.68
GFR (ml/min/1.73m ²)	75.6 [66.7– 94.3]	87.6 [78.9–102.7]	0.86 (0.8; 0.90)	0.001	37.7 [32.9–46.8]	41.3 [38.4-49.0]	0.91 (0.85; 0.98)	0.019	30.1 [21.9-42.6]	33.8 [25.7–47.1]	0.89 (0.82; 0.98)	0.018
FF	0.34 [0.30 – 0.36]	0.37 [0.32 – 0.41]	0.91 (0.83; 0.99)	0.028	0.28 [0.25 – 0.34]	0.29 [0.24 – 0.33]	0.97 (0.89; 1.05)	0.43	0.25 [0.22-0.28]	0.26 [0.22-0.31]	0.93 (0.84; 1.03)	0.18
RVR (mmHg/ml/min)	0.21 [0.15-0.26]	0.22 [0.16-0.29]	0.98 (0.91; 1.06)	0.87	0.38 [0.30-0.44]	0.37 [0.27 – 0.45]	1.01 (0.96; 1.06)	0.60	0.42 [0.29-0.59	0.43 [0.30-0.56]	0.99 (0.92; 1.06)	0.67
PGLO (mmHg)	59.9 [53.4- 64.1]	64.6 [58.4 – 66.8]	0.93 (0.87; 0.99)	0.024	49.3 [45.8–53.5]	49.7 [47.5 – 53.4]	0.99 (0.95; 1.03)	0.68	46.3 [41.3-52.7]	47.1 [41.4-52.7]	0.98 (0.95; 1.02)	0.37
R₄ (dyn*s/m⁵)	6666 [4273–9158]	6885 [4099-8352]	0.97 (0.89; 1.5)	0.42	14804 [11185- 19152]	15157 [11686– 19608]	0.98 (0.88; 1.08)	0.62	16811 [10324- 25388]	16941 [10002- 26013]	0.99 (0.90; 1.10)	0.87
R _e (dyn*s/m⁵)	3505 [3017-3782]	4085 [3293–4598]	0.86 (0.76; 0.96)	0.013	3092 [2905-3517]	3243 [2589 – 3804]	0.95 (0.86; 1.05)	0.32	2585 [2014–2858]	2919 [2545 - 3770]	0.89 (0.80; 0.98)	0.03

Table 2: Renal hemodynamics. FF: filtration fraction, RVR: renal vascular resistance, PGLO: intra-glomerular pressure R_a and R_e :afferent

and efferent glomerular arteriolar resistance. P-values < 0.05 in bold.

	DM2 Group				DM2-CKD group				CKD group			
	Empagliflozin Mean± SD	Placebo Mean± SD	Difference Mean (95% CI)	p-value	Empagliflozin Mean± SD	Placebo Mean± SD	Difference Mean (95% CI)	p-value	Empagliflozin Mean± SD	Placebo Mean± SD	Difference Mean (95% CI)	p-value
HbrAALC¢dyn*s/m⁵) (mmol/mol)	1785 圭 530	1828 圭 131	- <u>48</u> (794; 11)	p 6.04 24	1837 圭 346	1988 圭 380	-81 (-1 <u>47; 3</u> 16)	p 0.02 85	1638 圭 之36	1731 圭 之36	-43 (<u>7</u> 82; ₀ 5)	p ⁰.93 1
Heart rate (min ⁻¹)	67 ± 9	68 ± 9	-1 (-3; 1)	0.15	63 ± 10	64 ± 10	-1 (-2; 1)	0.5853	68 ± 8	69 ± 9	(-4; 1)	0.37

Table 3: Systemic hemodynamics. TVR: total vascular resistance. P-values < 0.05 in bold.</th>

Plasma glucose (mmol/L)	9.5 ± 2.1	11.1 ± 4.2	-1.6 (-3.4; 0.2)	p = 0.078	9.4 ± 2.4	9.6 ± 2.8	-0.1 (-1.2; 1.0)	P = 0.81	5.6 ± 1.1	5.9 ± 0.9	-0.2 (-0.7; 0.3)	P = 0.32
	Empagliflozin Geometric mean [IQR]	Placebo Geometric mean [IQR]	Difference Geometric mean ratio (95% CI)	p-value	Empagliflozin Geometric mean [IQR]	Placebo Geometric mean [IQR]	Difference Geometric mean ratio (95% CI)	p-value	Empagliflozin Geometric mean [IQR]	Placebo Geometric mean [IQR]	Difference Geometric mean ratio (95% CI)	p-value
Albumin/creatinine ratio* (mg/g)	347 [133–1087]	694 [286-2063]	0.50 (0.22; 1.12)	p = 0.07	205 [68–644]	399 [136 – 1326]	0.51 (0.31; 0.85)	P = 0.014	280 [57–1332]	350 [80-1921]	0.80 (0.54; 1.29)	p = 0.24
Urinary glucose (mmol/L)	87.9 [53.3 – 138.4]	0.2 [0.0-1.6]	-	p < 0.001	41.1 [38.0-66.2]	0.1 [0.0-0.1]	-	p < 0.001	11.6 [7.3–26.1]	0.0 [0.0-0.0]	-	p < 0.001

Table S2: Glycated hemoglobin (HbA1c), plasma glucose, albumin/creatinine ratio and urinary glucose. P-values < 0.05 in bold.</th>

* Only participants with an uACR > 30 mg/g at the placebo visit. N = 4 in the DM2 group. N = 14 in the DM2-CKD group. N = 11 in the

CKD group